Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: A safe and effective approach

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer.Methods: 82 patients with 1-3 inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity.Results: Median follow-up was 24 months (range 3-47). One, two and three years LC rate was 90%,80% and 75% (85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with <60 Gy (n = 52) was statistically significant, with a 1, 2 and 3 yrs LC of 97%,92% and 83% for the higher dose, compared to 85%,70% and 70% for the lower dose (p < 0.04). Median OS was 32 months. Actuarial OS rate at 1, 2 and 3 yrs was 85%,65% and 43%. Univariate analysis showed a correlation only between OS and cumulative GTV > 3 cm (p < 0.02). Median PFS was 14 months, with a PFS rate of 56% at 1 yr and 40% at 2-3 yrs, without correlation with the site and prescription dose (p < 0.48 and p < 0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity.Conclusions: SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.

Original languageEnglish
Article number619
JournalBMC Cancer
Volume14
Issue number1
DOIs
Publication statusPublished - Jul 27 2014

Fingerprint

Colorectal Neoplasms
Radiotherapy
Disease-Free Survival
Neoplasm Metastasis
Lung
Prescriptions
Survival
Liver
Survival Rate
Observational Studies
Liver Diseases
Radiation
Safety
Therapeutics

Keywords

  • Colorectal oligometastases
  • Liver
  • Lung
  • RapidArc
  • Stereotactic ablative radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics
  • Medicine(all)

Cite this

@article{9a83b37885bd4a6b8a44d3d454a99cf1,
title = "Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: A safe and effective approach",
abstract = "Background: To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer.Methods: 82 patients with 1-3 inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity.Results: Median follow-up was 24 months (range 3-47). One, two and three years LC rate was 90{\%},80{\%} and 75{\%} (85{\%},75{\%} and 70{\%} for lung and 95{\%}, 90{\%} and 85{\%} for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with <60 Gy (n = 52) was statistically significant, with a 1, 2 and 3 yrs LC of 97{\%},92{\%} and 83{\%} for the higher dose, compared to 85{\%},70{\%} and 70{\%} for the lower dose (p < 0.04). Median OS was 32 months. Actuarial OS rate at 1, 2 and 3 yrs was 85{\%},65{\%} and 43{\%}. Univariate analysis showed a correlation only between OS and cumulative GTV > 3 cm (p < 0.02). Median PFS was 14 months, with a PFS rate of 56{\%} at 1 yr and 40{\%} at 2-3 yrs, without correlation with the site and prescription dose (p < 0.48 and p < 0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity.Conclusions: SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.",
keywords = "Colorectal oligometastases, Liver, Lung, RapidArc, Stereotactic ablative radiotherapy",
author = "Tiziana Comito and Luca Cozzi and Elena Clerici and Campisi, {Maria C.} and Liardo, {Rocco Luca E} and Pierina Navarria and AnnaMaria Ascolese and Angelo Tozzi and Cristina Iftode and {De Rose}, Fiorenza and Elisa Villa and Nicola Personeni and Lorenza Rimassa and Armando Santoro and Antonella Fogliata and Pietro Mancosu and Stefano Tomatis and Marta Scorsetti",
year = "2014",
month = "7",
day = "27",
doi = "10.1186/1471-2407-14-619",
language = "English",
volume = "14",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer

T2 - A safe and effective approach

AU - Comito, Tiziana

AU - Cozzi, Luca

AU - Clerici, Elena

AU - Campisi, Maria C.

AU - Liardo, Rocco Luca E

AU - Navarria, Pierina

AU - Ascolese, AnnaMaria

AU - Tozzi, Angelo

AU - Iftode, Cristina

AU - De Rose, Fiorenza

AU - Villa, Elisa

AU - Personeni, Nicola

AU - Rimassa, Lorenza

AU - Santoro, Armando

AU - Fogliata, Antonella

AU - Mancosu, Pietro

AU - Tomatis, Stefano

AU - Scorsetti, Marta

PY - 2014/7/27

Y1 - 2014/7/27

N2 - Background: To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer.Methods: 82 patients with 1-3 inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity.Results: Median follow-up was 24 months (range 3-47). One, two and three years LC rate was 90%,80% and 75% (85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with <60 Gy (n = 52) was statistically significant, with a 1, 2 and 3 yrs LC of 97%,92% and 83% for the higher dose, compared to 85%,70% and 70% for the lower dose (p < 0.04). Median OS was 32 months. Actuarial OS rate at 1, 2 and 3 yrs was 85%,65% and 43%. Univariate analysis showed a correlation only between OS and cumulative GTV > 3 cm (p < 0.02). Median PFS was 14 months, with a PFS rate of 56% at 1 yr and 40% at 2-3 yrs, without correlation with the site and prescription dose (p < 0.48 and p < 0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity.Conclusions: SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.

AB - Background: To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer.Methods: 82 patients with 1-3 inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity.Results: Median follow-up was 24 months (range 3-47). One, two and three years LC rate was 90%,80% and 75% (85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with <60 Gy (n = 52) was statistically significant, with a 1, 2 and 3 yrs LC of 97%,92% and 83% for the higher dose, compared to 85%,70% and 70% for the lower dose (p < 0.04). Median OS was 32 months. Actuarial OS rate at 1, 2 and 3 yrs was 85%,65% and 43%. Univariate analysis showed a correlation only between OS and cumulative GTV > 3 cm (p < 0.02). Median PFS was 14 months, with a PFS rate of 56% at 1 yr and 40% at 2-3 yrs, without correlation with the site and prescription dose (p < 0.48 and p < 0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity.Conclusions: SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.

KW - Colorectal oligometastases

KW - Liver

KW - Lung

KW - RapidArc

KW - Stereotactic ablative radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84907011514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907011514&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-14-619

DO - 10.1186/1471-2407-14-619

M3 - Article

C2 - 25163798

AN - SCOPUS:84907011514

VL - 14

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 619

ER -